Investigational Drug Details
| Drug ID: | D353 |
| Drug Name: | Sulfonylurea |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | 140987867 |
| CasNo: | -- |
| Repositioning for NAFLD: | No |
| SMILES: | S(=O)(=O)=NC(=O)N.S(=O)(=O)=NC(=O)N |
| Structure: |
|
| InChiKey: | YDMLDADNVSAMLD-UHFFFAOYSA-N |
| Molecular Weight: | 244.21 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 4 completed (NCT02649465) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0066 | NCT02649465 | Phase 4 | Completed | No Results Available | November 11, 2015 | July 2, 2021 | Details |
| L0593 | JPRN-UMIN000020544 | Not selected | Not Recruiting | No Results Available | 13/01/2016 | 21 May 2019 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00255 | 35163991 | Molecules | Sitagliptin Is More Effective Than Gliclazide in Preventing Pro-Fibrotic and Pro-Inflammatory Changes in a Rodent Model of Diet-Induced Non-Alcoholic Fatty Liver Disease. | Details |
| A01347 | 34779535 | Hepatology | Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. | Details |
| A01811 | 34606980 | Endocr Pract | Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials. | Details |
| A02366 | 34401141 | Ann Med Surg (Lond) | Prevalence of fatty liver disease and its associated factors among Jordanian patients with type 2 diabetes mellitus: A cross-sectional study. | Details |
| A03104 | 34129693 | Hepatology | Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study. | Details |
| A04814 | 33497019 | Liver Int | Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis. | Details |
| A05041 | 33397230 | Curr Pharm Des | Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular Disease. | Details |
| A06074 | 33015726 | Curr Diab Rep | Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. | Details |
| A07866 | 32329963 | J Diabetes Investig | Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study. | Details |
| A08201 | 32207583 | Adv Clin Exp Med | Advanced glycation end products derived from serum albumin modification by glucose (AGE-1) reflect clustering of lipid-associated metabolic abnormalities and are decreased in patients treated with acarbose: A cross-sectional study. | Details |
| A08867 | 31956961 | Diabetes Ther | Study Protocol for Pleiotropic Effects and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. | Details |
| A10550 | 31292843 | Clin J Gastroenterol | Long-term luseogliflozin therapy improves histological activity of non-alcoholic steatohepatitis accompanied by type 2 diabetes mellitus. | Details |
| A11204 | 31000862 | J Pak Med Assoc | Expert Opinion: Use of sodium glucose co-transporter type-2 inhibitors in South Asian population -The Pakistan perspective. | Details |
| A11769 | 30758417 | Rev Assoc Med Bras (1992) | The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data. | Details |
| A12660 | 30341231 | Postgrad Med J | Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. | Details |
| A13245 | 30066148 | Diabetologia | Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. | Details |
| A16488 | 28358980 | Cochrane Database Syst Rev | Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. | Details |
| A16925 | 28089623 | Dig Liver Dis | Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? | Details |
| A18464 | 27110380 | BMJ Open Gastroenterol | Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. | Details |
| A22315 | 24669954 | Expert Opin Drug Metab Toxicol | Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. | Details |